Since the beginning of this year, the global economy has maintained a moderate recovery and the growth rate of international trade has accelerated. In the field of medicine, although traditional foreign trade has weakened its competitive advantages and fierce competition in industries and prices, it has supported the development of pharmaceutical foreign trade Of the new momentum is accelerating the accumulation of quality and efficiency improved steadily, the structure of foreign trade continued to optimize the pattern of stable and favorable medical foreign trade has been formed throughout the year.
In the first three quarters of 2017, China's total foreign trade in medicine was 84.953 billion U.S. dollars, up 10.71% over the same period of 2006. Of this total, the exports were 43.678 billion U.S. dollars, up by 5.61% over the same period of last year; the import was 41.275 billion U.S. dollars, up 16.66% over the same period of 2006. The surplus was 2.403 billion U.S. dollars, down 59.8% . Subdivided into three major categories of commodities, exports of Chinese medicine 2.6 billion US dollars, down slightly by 0.27%; Western exports of 25.395 billion US dollars, up 8.44%; medical equipment exports 15.684 billion US dollars, an increase of 2.29%.
The first three quarters of analysis
Import growth rate is better than exports, pharmaceutical trade balance development
January to September, China's import of medical products 41.275 billion US dollars, almost balanced with the export volume, import growth rate higher than the export 11.05 percentage points, among which, the prices of traditional Chinese medicine and medical equipment increased at a lower price, while that of western medicine doubled.
At present, China's imports are dominated by high-end medical equipment, pharmaceutical equipment and western medicine and are highly complementary to the domestic industries. They can improve domestic supply and help industrial restructuring, upgrading and livelihood improvement.
Mainstream export markets remained stable with significant growth in the Belt and Road initiative
The first three quarters of China's pharmaceutical exports to 225 countries and regions, Asia, Europe and North America are the major export markets, exports were 179.25 billion, 114.2 million and 8.568 billion US dollars, accounting for up to 86.8%. Europe and North America China's import of pharmaceutical products is the main source of imports from North America, an increase of 17.73%, imports from Europe increased 18.05%, reflecting the advantages of European and American products is still solid.
In addition, the country's import and export of pharmaceuticals along the Belt and Road rose by 19.95% and 5.75% respectively over the same period of last year with a 144.32% increase in imports from Iran and a 94.72% increase in imports from Turkey. The Belt and Road initiative is underway in medicine Solid progress in mutually beneficial cooperation in the field.
Private-owned main force have their own advantages, obvious benefits
Private-owned and foreign-funded enterprises are the two main forces in the foreign trade of medical insurance products in our country, both of which have steady growth and relatively large increases in performance.
From January to September, private-owned enterprises accounted for 79.62% of the total exporters, accounting for 67.72% of the total exports and 53.69% of the total exports, an increase of 8.05% over the same period of last year.
In the area of imports, foreign-funded enterprises have obvious advantages. The number of importers accounts for 37.36% of the total imports, and the import amounts to 68.77% and 61.05% respectively. The import volume has increased by 19.34% over the same period of last year.
The export of coastal provinces and cities pick up, northeast and central and western hot and cold
From January to September, the top five exports accounted for Jiangsu, Zhejiang, Guangdong, Shanghai and Shandong, with the growth rate of 14.95% in Jiangsu, the largest export province among the three northeastern provinces And the central and western provinces are in contrast: Ningxia grew by 28.32% and Xinjiang increased by 18.18%, while Guizhou and Yunnan also dropped by 54.68% and 26.83% respectively from the first quarter of this year to 4.8% and 2.89% at present; the three northeastern provinces fell across the board While the exports of Heilongjiang, Jilin and Liaoning decreased by 19.98%, 12.58% and 2.76% respectively, and the pattern of weakening of the east, the west and the west would not change much in the short term.
Five major export problems
1, raw material drug competition disorder
In recent years, the state has made great efforts to promote supply-side structural reforms and made progress, but the problem of overcapacity of bulk raw materials is hard to be solved in the short term. Facing the fierce market competition, the export prices of bulk raw materials are falling all the time, , Profit margins continue to be squeezed.At the same time, some domestic minority pharmaceutical raw materials due to fewer manufacturers, low output, there is a monopoly price increase or circulation, the preparation of the exclusive purchase of pharmaceutical companies, resulting in other formulations manufacturers have to get high prices And then pushed up the export price of the formulation.Many preparation companies because of the goods out of stock, such as cimetidine, lidocaine, oxytocin and other niche products directly to the market.
2, environmental pressure
First, a large number of raw material drug companies are facing the dilemma of limited production due to environmental problems such as Taizhou, Zhejiang Province, there are already many pharmaceutical intermediates have been shut down, Beijing requires raw material drug manufacturers in November heating season all discontinued production, Beijing, Tianjin and Hebei require the pharmaceutical industry to implement peak-shifting production during the heating season.
Second, the pharmaceutical industry pollution standards gradually improved.Revised version of the "emission standards for air pollutants in the pharmaceutical industry," with reference to the experience of Europe, the United States and Japan and other countries, the implementation of the sewage permit system, some of which indicators more stringent than the more developed countries.
Third, long-term suspension of production led to a shortage of domestic products related products, some international orders can not be implemented normally, directly facing the risk of economic compensation and loss of the market.
For example, some leading pharmaceutical enterprises in Hebei Province have invested heavily in environmental upgrading and upgrading, although the relevant requirements have been met, they are treated as "non-discriminatory" with respect to non-compliance with environmental protection measures before the stop-limiting measures are implemented.
